Original product for prostate hyperplasia treatment; mechanisms of preclinical action

Abstract

Adenoprosin product is based on the exploitation of certain entomological resources, whose biological systems are analogs with the human ones in a higher percent than other natural sources. This compatibility is concretized in a higher responsiveness of cellular structures to the action of the entomological biocomplex with an optimized design towards a particular therapeutical target. Adenoprosin is involved in inflammatory processes associated with static and dynamic mechanisms of prostate hyperplasia. The „in vitro” specific action was investigated using standardized cell lines (PWR-1E - androgenresponsive and DU-145 - prostate adenocarcinoma metastasis; hormone independent cells) and experimental positive controls (dutasteride - drug involved in hormone -dependent aberrant proliferative mechanisms induced by testosterone; methotrexate - cell division inhibitor; dexamethasone - anti by its anti-apoptotic, anti-proliferative and anti-inflammatory biological activity, proved by methods of performant cellular and molecular multi-parametric analysis. It was highlighted the stop of IL6 and IL8 cytokines extracellular release in stimulating conditions with pro-inflammatory agents (phorbol-myristateacetate- PMA and tumor necrosis factor - TNFa). As well as, Adenoprosin shows significant action on extracellular signaling pathways of tumor progression and invasion, inhibiting IL6 cytokine - morbidity mediator in prostate cancer and VEGF - responsible of the onset of angiogenesis in metastatic -process, ffie preclinical studies revealed an optimum efficacy / toxicity profile, remarkable in the actual tendencies of therapeutical capitalization of natural raw materials with significant biological efficiency and minimal side effects. In recent years, the pathologies resulted from prostate disorders had a rising incidence, Adenoprosin covering an important therapeutical niche on the pharmaceutical market. The research was conducted as part of the project ENTOMED / Ctr DPST 26/2013.

Produsul Adenoprosin se bazeaza pe exploatarea unor anumite resurse entomologice ale căror sisteme biologice sunt analoge celor umane intr-un procent ridicat fata de alte surse naturale. Aceasta compatibilitate este concretizata printr-o responsivitate superioara a structurilor celulare la acţiunea biocomplexului entomologie cu design optimizat către o anumita tinta terapeutica. Adenoprosin intervine in procese inflamatorii asociate cu mecanisme statice si dinamice implicate in hiperplazia de prostata. Acţiunea specifica in vitro a fost investigata utilizând linii celulare standardizate (PWR-1E - androgen-responsiva si DU-145 - metastaza de adenocarcinom de prostata, hormon independenta) si martori pozitivi experimentali (dutasterid - medicament ce intervine in mecanismele aberant proliferative hormon-dependente induse de testosteron, metrotrexat - inhibitor diviziune celulara, dexametazona - agent antiinflamator) .Efectul produsului Adenoprosin este susţinut de activitatea biologica antiapoptotica, antiproliferativa si antiinflamatoare demonstrate in vitro prin metode performante de analiza multiparametrica celulara si moleculara. S-a evidenţiat stoparea eliberării de citokine IL6 si IL8 in condiţii de stimulare cu agenţi pro-inflamatorii (forbol miristat acetat-PMA si factor necrotic tumoral-TNFa). De asemenea, Adenoprosin manifesta acţiune semnificativa pe caile de semnalizare extracelulara a progresiei si invaziei tumorale inhibând citokina IL6 - mediator al morbidităţii in cancerul de prostata si VEGF - factor declanşator al angiogenezei in metastazare. Studiile preclinice au evidenţiat de asemenea, un profil eficacitate / toxicitate optim, remarcabil in tendinţele actuale de valorificare terapeutica a materiilor prime naturale cu activitate biologica eficienta si efecte secundare minime. In ultimii ani, patologiile rezultate din disfunctiile prostatei au o incidenţa crescută, produsul Adenoprosin acoperind o nisa terapeutica importanta in piaţa farmaceuticelor. Cercetările s-au realizat in cadrul proiectului ENTOMED / Ctr26 DPST/2013.